In reply: - 22/01/21
Doi : 10.1016/j.annemergmed.2020.09.440
Le texte complet de cet article est disponible en PDF.
| Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. Dr. Stopyra receives research funding from National Center for Advancing Translational Sciences/National Institute of Health (KL2TR001421), Health Resources and Services Administation (H2ARH39976-01-00), National Heart Lung and Blood Institute (U01HL123027), Roche Diagnostics, and Abbott Point of Care. He has provided paid consulting to Roche Diagnostics. Dr. Mahler receives research funding from Roche Diagnostics, Abbott Point of Care, Ortho Clinical Diagnostics, Creavo Medical Technologies, Patient Centered Outcomes Research Institute, Agency for Health Research and Quality, Health Resources and Services Administration (H2ARH39976-01-00), and National Heart Lung and Blood Institute (1 R01 HL11826301). He is a consultant for Roche Diagnostics and Amgen and is the chief medical officer for Impathiq Inc. |
© 2020
American College of Emergency Physicians. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 77 - N° 2
P. 278-279 - février 2021 Retour au numéro
Article précédent
- Can HEART Criteria Be Used as an Ideal Tool for Multilayer Clinical Outcome Predictions?
- Chet D. Schrader, Stefan H. Meyering, Hao Wang
- Is Tranexamic Acid for Upper Gastrointestinal Bleeding Under Debate?
- Yu-Wan Ho, Po-Lin Lee, Yi-No Kang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?